May. 13 at 7:25 PM
$AIFF The Firefly Neuroscience / Cognito Therapeutics HOPE trial is likely catalytic because it may become the first major longitudinal proof that Firefly’s BNA/CLEAR platform can detect meaningful brain-state progression in a controlled therapeutic setting.
Firefly does not need perfection — it needs useful, repeatable probability. If the trial shows measurable tracking of neurological change, the market narrative could rapidly shift from “experimental EEG analytics” to “clinically actionable neuroinformatics platform.”
A positive outcome would also validate the importance of CLEAN longitudinal data and CLEAR normalization, potentially accelerating pharma partnerships, clinic adoption, DoD interest, and confidence that Firefly’s data flywheel is beginning to produce actionable biomarker intelligence.
